Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 January, 2018 00:17 IST
Zydus receives approval from USFDA for Mesalamine suppositories
Source: IRIS | 11 Aug, 2017, 05.12PM
Comments  |  Post Comment

Zydus Cadila has received the tentative approval from the USFDA to market Mesalamine Suppositories for rectal use, 1000 mg.

Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical plant at Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 17.55, or 3.77%, to settle at Rs 482.95. The total volume of shares traded was 401,757 at the BSE (Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Kalpataru Power bags new orders worth Rs 8.71 bn - 22-Jan-2018 16:21
Infosys inks pact with A.S. Watson Group - 22-Jan-2018 15:50
Reliance Nippon Life inks pact with Bank of Maharashtra - 22-Jan-2018 15:10
Reliance Nippon Life inks pact with Bank of Maharashtra - 22-Jan-2018 15:10
Larsen & Toubro launches second offshore patrol vessel - 22-Jan-2018 10:06
ONGC acquires 51.11% stake of President of India in HPCL - 22-Jan-2018 10:01
ONGC acquires 51.11% stake of President of India in HPCL - 22-Jan-2018 10:01
IL&FS Transportation Networks receives LoA for road project in J&K - 22-Jan-2018 09:52
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer